-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Zentalis Pharmaceuticals Announces First Patient Dosed In Aspenova Phase 3 Trial Of Azenosertib In Patients With Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Reuters·05/05/2026 12:01:22

Please log in to view news